Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Published:2023-04 Issue:10382 Volume:401 Page:1079-1090
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Craig Timothy J,Reshef Avner,Li H Henry,Jacobs Joshua S,Bernstein Jonathan A,Farkas Henriette,Yang William H,Stroes Erik S G,Ohsawa Isao,Tachdjian Raffi,Manning Michael E,Lumry William R,Saguer Inmaculada Martinez,Aygören-Pürsün Emel,Ritchie Bruce,Sussman Gordon L,Anderson John,Kawahata Kimito,Suzuki Yusuke,Staubach Petra,Treudler Regina,Feuersenger Henrike,Glassman Fiona,Jacobs Iris,Magerl Markus

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. The international WAO/EAACI guideline for the management of hereditary angioedema–the 2021 revision and update;Maurer;Allergy,2022

2. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema;Busse;J Allergy Clin Immunol Pract,2021

3. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients;Agostoni;Medicine (Baltimore),1992

4. The burden of illness in patients with hereditary angioedema;Banerji;Ann Allergy Asthma Immunol,2013

5. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe;Aygören-Pürsün;Orphanet J Rare Dis,2014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor XII contact activation can be prevented by targeting 2 unique patches in its epidermal growth factor-like 1 domain with a nanobody;Journal of Thrombosis and Haemostasis;2024-09

2. Développement clinique des thérapeutiques anti-facteur XII ciblant la thrombo-inflammation;La Revue de Médecine Interne;2024-08

3. Current and Emerging Therapeutics in Hereditary Angioedema;Immunology and Allergy Clinics of North America;2024-08

4. Progress towards permanent respiratory support;Current Opinion in Organ Transplantation;2024-07-10

5. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks;New England Journal of Medicine;2024-07-04